Association of TP53 Mutation Status and Sex with Clinical Outcome in Non–Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Retrospective Cohort Study
Cancer Research and Treatment · 2025
DOI: 10.4143/crt.2024.046 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Songji Choi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Lung Neoplasms, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Seoul National University Bundang Hospital.
Abstract (Originalsprache)
Purpose
Some studies suggest that TP53 mutations are associated with the response to immune checkpoint inhibitors (ICI) in patients with non–small cell lung cancer (NSCLC) and also contribute to sex disparities in several cancers. Thus, we hypothesized that TP53 mutations might serve as sex-dependent genomic biomarkers of ICI treatment response in patients with NSCLC.Materials and Methods Clinical data of 100 patients with metastatic NSCLC treated with ICI monotherapy at Seoul National University Bundang Hospital (SNUBH) were retrospectively reviewed. Genomic and clinical datasets of The Cancer Genome Atlas and an ICI-treated lung cancer cohort (cBioPortal) were also analyzed.
Results
In SNUBH cohort, no statistically significant difference was observed in the median progression-free survival (PFS) according to TP53 mutation status (p=0.930); however, female patients with TP53 mutations (MT) had a significantly prolonged median PFS compared to wild-type (WT) (6.1 months in TP53 MT vs. 2.6 months in TP53 WT; p=0.021). Programmed death-ligand 1 (PD-L1) high (≥ 50%) expression was significantly enriched in female patients with TP53 MT (p=0.005). The analysis from publicly available dataset also revealed that females with NSCLC with TP53 MT showed significantly longer PFS than those with TP53 WT (p < 0.001). In The Cancer Genome Atlas analysis, expression of immune-related genes, and tumor mutation burden score in TP53 MT females were higher than in males without TP53 MT.
Conclusion
Female patients with NSCLC with TP53 mutations had high PD-L1 expression and showed favorable clinical outcomes following ICI therapy, suggesting a need for further research to explore the role of TP53 mutations for sex disparities in response to ICI therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
- Precision Medicine Center, Seoul National University Bundang Hospital, Seongnam, Korea.
Förderung
- Seoul National University Bundang Hospital
Zitieren
APA
Choi, S., Kim, S. H., Lee, S., Seo, J., Kang, M., Jung, E. H., Kim, S. A., Suh, K. J., Lee, J. Y., Kim, J. W., Kim, J. W., Lee, J. O., Kim, Y. J., Lee, K. W., Kim, J. H., Bang, S. M., & Lee, J. S. (2025). Association of TP53 Mutation Status and Sex with Clinical Outcome in Non–Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Retrospective Cohort Study. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.046
Vancouver
Choi S, Kim SH, Lee S, Seo J, Kang M, Jung EH, et al. Association of TP53 Mutation Status and Sex with Clinical Outcome in Non–Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Retrospective Cohort Study. Cancer Research and Treatment. 2025. doi:10.4143/crt.2024.046
BibTeX
@article{Choi2025,
author = {Choi, Songji and Kim, Se Hyun and Lee, Sejoon and Seo, Jeongmin and Kang, Minsu and Jung, Eun Hee and Kim, Sang-A and Suh, Koung Jin and Lee, Ji Yun and Kim, Ji-Won and Kim, Jin Won and Lee, Jeong-Ok and Kim, Yu Jung and Lee, Keun-Wook and Kim, Jee Hyun and Bang, Soo-Mee and Lee, Jong Seok},
title = {Association of TP53 Mutation Status and Sex with Clinical Outcome in Non–Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Retrospective Cohort Study},
journal = {Cancer Research and Treatment},
year = {2025},
doi = {10.4143/crt.2024.046}
}
EUVIMED